Melancholia Clinical Trial
Official title:
Serotonin Transporter Density in Late-life Depression With and Without Dementia
This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20
AD depressive); each evaluable subject involved in this study must fulfill all the inclusion
and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations,
laboratory examinations and collecting of adverse events.
This study is expected to be completed in a period of 3 years.
Depression and dementia are the two common psychiatric disorders in the elder subjects. Alzheimer's disease (AD) is the most frequent cause of dementia and about 20% of them have depression. Depression subjects are associated with more rapid cognitive decline, a poorer response to treatment. Post mortem study showed close relationship between AD and disruptions of the serotonergic system, including loss of serotnergic neurons at brain stem. However, the alternations in presynaptic serotonin function relative to demented or non-demented subjects remain to be investigated in living subjects. In this study, the investigators will collect 40 elder subjects (i.e., age above or equal to 50 years old). The serotonin transporter activity will be compared between subjects with or without dementia using I-123 ADAM images. The single photon emission tomography (SPECT) will be compared to recent (within 6 months) F-18 FDG PET images for further investigation. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Completed |
NCT02989727 -
Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
|
Phase 4 | |
Completed |
NCT00000378 -
Antidepressant Treatment of Melancholia in Late Life
|
Phase 4 | |
Recruiting |
NCT04160377 -
A Clinical Trial of Fluvoxamine for Melancholia
|
Phase 2 |